Skip to main content
. 2024 Jan 26;15:1324299. doi: 10.3389/fphar.2024.1324299

TABLE 3.

Summary of treatment-emergent adverse events.

Tolvaptan (n = 11)
Number of events n (%)
Any TEAEs 20 9 (81.8)
Mild 15 7 (63.6)
Moderate 4 3 (27.3)
Severe 1 1 (9.1)
Drug-related TEAEs 12 7 (63.6)
Mild 9 5 (45.5)
Moderate 3 3 (27.3)
Severe 0 0
Any SAEs 0 0
Any TEAEs reported in ≥ 2 patients, termed by PT
Thirst 5 5 (45.5)
Pollakiuria 4 4 (36.4)
Dry mouth 3 3 (27.3)
Dyspnea 2 2 (18.2)

Abbreviations: PT, preferred term; SAE, serious adverse event; TEAE, treatment emergent adverse event.